. 2025 Sep 25;8:573. doi: 10.1038/s41746-025-01954-y

Table 2.

Summary of drugs in development that utilized AI

Drug compound	Company	Mechanism of action	Disease	Role of AI in drug discovery
DSP 1181¹²	Exscientia & Sumitomo Dainippon Pharma	Serotonin 5 HT1A receptor agonist	Obsessive compulsive disorder	De novo molecular design
AI designed antibody against TL1A¹⁴⁰	Absci	TL1A targeted antibody	Inflammatory bowel disease	De novo molecular design
ISM3091¹⁴¹	Insilico Medicine & Exelixis	IND ready small molecule inhibitor of anticancer target	Cancer	Target Identification & De novo molecular design
Small molecule KAT6A inhibitor¹⁴²	Insilico Medicine & Stemline therapeutics	Small molecule inhibitor for anticancer target	Cancer	De novo molecular design
INS018_055¹⁴³	Insilico Medicine	Small-molecule inhibitor of antifibrotic target TRAF2- and NCK-interacting kinase (TNIK)	Idiopathic pulmonary fibrosis	Target Identification & De novo molecular design
Halicin¹⁴⁴	MIT	Antibiotic against E coli and Acinetobacter Baumannii	Antibiotic	Drug Repurposing
LP-300¹⁴⁵	Lantern	Interacts with tyrosine kinase inhibitor (TKI) receptors via cysteine modification.	Relapsed advanced lung cancer	Patient Stratification
LP 184¹⁴⁶	Lantern	Activated via Prostaglandin Reductase 1 (PTGR1) to its cytotoxic form in cancer cells	Triple negative breast cancer	Lead Optimization and Patient Stratification
LP 284¹⁴⁷	Lantern	Damages DNA in cancer cells	Refractory lymphomas	Lead Optimization and Patient Stratification

TL1A tumor necrosis factor-like cytokine 1A.